|
[1]
|
Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640. |
|
[2]
|
Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157. |
|
[3]
|
Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554. |
|
[4]
|
Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743. |
|
[5]
|
Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033. |
|
[6]
|
Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672. |
|
[7]
|
Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152. |
|
[8]
|
Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212. |
|
[9]
|
Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110. |
|
[10]
|
Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808. |
|
[11]
|
Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193. |
|
[12]
|
Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394. |
|
[13]
|
Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323. |
|
[14]
|
Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843. |
|
[15]
|
Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775. |
|
[16]
|
Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868. |
|
[17]
|
o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251. |
|
[18]
|
胡 萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70. |
|
[19]
|
Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831. |
|
[20]
|
Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353. |
|
[21]
|
Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876. |
|
[22]
|
Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668. |
|
[23]
|
Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489. |
|
[24]
|
Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629. |
|
[25]
|
Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498. |
|
[26]
|
胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576. |
|
[27]
|
Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930. |
|
[28]
|
Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725. |
|
[29]
|
Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419. |
|
[30]
|
Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715. |
点击查看大图
下载:
